INC Research/inVentiv Health has changed its brand identity to Syneos Health effective January 4, 2018. Purpose-built for modern biopharmaceutical market realities, Syneos Health is the only fully integrated, end-to-end biopharmaceutical solutions organization.
Syneos Health solutions are fully integrated to deliver better processes and smarter practices to speed the delivery of biopharmaceutical therapies to market.
“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. “Unlike traditional CROs and commercialization businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale. Our Biopharmaceutical Acceleration Model is unique to the industry, and from this ambitious vision, Syneos Health was born.”
The company’s integrated platform leverages a combination of clinical and commercial solutions. Behavioral insights are leveraged to accelerate clinical trial recruitment, and therapeutic knowledge infuses multi-channel commercial programs to better engage increasingly hard-to-reach stakeholders.
In connection with the name change, Syneos Health common shares are expected to trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by January 9, 2018. Until then, Syneos Health will continue to be listed under INC Research Holdings and the symbol “INCR.”